UK pharma to declare doctor payments
November 4, 2010Medical Communications, Sales and Marketing ABPI, ABPI Code of Practice, advisory boards, healthcare professionals, pharma industry standards
Pharma companies in the UK have agreed to restrict their promotional giveaways and to declare payments to doctors. Another common …
New Commercial Realities
November 4, 2010Sales and Marketing Kinapse, White paper
Faced with a changing healthcare environment and the prospect of diminishing commercial returns, pharmaceutical companies must undertake a fundamental and …
Digital Pharma: Diabetes patients and Facebook
November 3, 2010Medical Communications Digital Pharma blog, Facebook, diabetes, patient information, social networking
A quarter of comments on the 15 largest Facebook communities for diabetes patients are promotional – generally for non-FDA approved …
Medivir appoints Charlotte Edenius
November 3, 2010Research and Development Charlotte Edenius, Medivir, appointment, research and development
Swedish specialty pharmaceutical company Medivir has appointed Charlotte Edenius to the newly created position of VP of research and development …
The utility of next generation sequencing in drug development
November 3, 2010Research and Development Dr Cheng Eng Ang, Illumina, Source BioScience, drug development, genomics, human genome, next generation sequencing
Drug development studies are extremely expensive, costing many millions of pounds and taking up to 12 years to bring a …
BMS skin cancer drug hits US regulatory delay
November 3, 2010Research and Development BMS, Bristol-Myers Squibb, FDA, MDX010-020 trial, ipilimumab, skin cancer
US regulators have announced they need more time to assess Bristol-Myers Squibb’s skin cancer treatment ipilimumab. The FDA will not …
Lundbeck issues Lexapro patent warning
November 3, 2010Sales and Marketing Azilect, Cipralex, Forest Laboratories, Lexapro, Lundbeck, Xenazine
Neurological disorder specialist Lundbeck has posted a modest growth in revenue for the third quarter, but warned the looming patent …
Almirall and Forest’s phase III COPD drug misses goal
November 3, 2010Research and Development Aclidinium bromide, Almirall, COPY, Forest, Forest Laboratories, chronic obstructive pulmonary disease
Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …
Pfizer Q3 profits hit hard
November 3, 2010Sales and Marketing Liptior sales, Pfizer, Pfzier Q3 results, Wyeth
The integration of Wyeth into Pfizer continues to drive its revenue growth, but at a cost – charges from the …
Lonza says contract manufacturing business is recovering
November 2, 2010Manufacturing and Production API, Lonza, contract manufacturing, pharma manufacturing
Lonza said its contract manufacturing business seems to be enjoying a return to form in the third quarter, despite continued …
Pfizer pulls more Lipitor over odour problem
November 2, 2010Manufacturing and Production Lipitor, Lipitor recall, Pfizer, manufacturing compliance, recalls
Pfizer has widened its Lipitor recall after yet another incident in which consumers reported a musty smell emanating from bottles …
Lilly to open diabetes research centre in China
November 2, 2010Research and Development China, Eli Lilly & Co, Lilly Research Laboratories in China, diabetes, lilly
The march of foreign pharma companies into China is to continue with Eli Lilly and Co’s opening of a diabetes …
Nycomed expands China presence with Techpool stake
November 2, 2010Research and Development, Sales and Marketing China, Guangdong Techpool biopharma, Nycomed, emerging markets, emerging pharma markets
Swiss-based Nycomed has acquired a majority stake in Guangdong Techpool biopharma in China, extending its presence in the top tier …
BMS faces approval block unless GMP issues are resolved
November 2, 2010Manufacturing and Production BMS, Bristol-Myers Squibb, FDA, Puerto Rico, belatacept, manufacturing compliance, pharma manufacturing
Bristol-Myers Squibb has been threatened with a block on approvals of certain new drugs, including a biologic for preventing organ …
Lundbeck UK appoints senior management team
November 2, 2010Research and Development, Sales and Marketing Amanda Badrick, Andy Davis, Andy Jones, Helen Carberry, Lundbeck, Steve Ferguson, appointment, recruitment, research and development, sales and marketing
Lundbeck UK has formed a new senior management team, appointing Steve Ferguson, Andy Davis, Andy Jones, Helen Carberry and Amanda …
Abbott hep C drug ABT-450/r impresses in mid-stage trial
November 2, 2010Research and Development ABT-450/r, Abbott, Abbott Laboratories, American Liver Disease congress, Enanta Pharmaceuticals, Norvir, hepatitis C
Mid-stage trial results of Abbott Laboratories’ oral hepatitis C drug ABT-450/r have impressed at the American Liver Disease congress. The …
Regulators must catch up with medical science, says FDA
November 2, 2010Research and Development, Sales and Marketing Advancing Regulatory Science, Critical Path Initiative’, Dr Margaret Hamburg, FDA, regulatory affairs
The head of the FDA has declared a need for ‘regulatory science’ to catch up with the advances in medical …
6 tips for regulatory compliance in logistics
November 2, 2010Manufacturing and Production, Research and Development Biocair, GMP, International Council for Harmonisation, pharma logistics, regulatory compliance
Regulation! Regulation! Regulation! Never has our business been more highly regulated than it is today. Seemingly, rules change every day. …
‘Therapeutic clusters’ collaboration launched
November 2, 2010Research and Development ABPI, BIA, Immunology Initiative, Medical Research Council, Office for Strategic Co-ordination of Health and Research, Therapeutic Capability Clusters’, UCB, therapeutic clusters
Two initiatives linking the pharma industry and government-funded research and academia are to go ahead, with the aim of reviving …
Relief as life sciences spared in UK cutbacks
November 1, 2010Research and Development ABPI, Comprehensive Spending Review, Diamond Synchrotron, UK Centre for Medical Research Innovation, UKCMRI, government, science funding
UK government funding for life sciences R&D has been spared from the deep cuts some had feared. Many in the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
